Magnesium and Dexmedetomidine in Pheochromocytoma

Completed

• Conditions: Hemodynamic Instability; Phaeochromocytoma Crisis
• Interventions: Drug: Magnesium-Dexmedetomidine

• Registration Number: NCT05102058
• Lead Sponsor: Istanbul University

Brief Summary

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2011-01-01
• Primary Completion: 2020-03-01
• Study Completion: 2020-03-01
• Status Verified: 2021-10
• Study First Submitted: 2021-10-20
• Study First Submitted QC: 2021-10-20
• Last Update Submitted: 2021-10-20
• Study First Posted: 2021-11-01
• Last Update Posted: 2021-11-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

• American Society of Anesthesiologists classification (ASA) 1-3
• high urinary catecholamine or metabolites
• tumor sizes < 5 cm
• body mass index (BMI) <35 kg/m2

Exclusion Criteria

• open surgery
• bilateral masses
• tumor larger than 5 cm
• incomplete data

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Magnesium-dexmedetomidine therapy group (GMD)	Magnesium-Dexmedetomidine	Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively.

Primary Outcome Measures

Name	Time	Method
Sodium nitroprusside (SNP) requirement	intraoperative period	intraoperative hypertensive episodes requiring SNP therapy

Secondary Outcome Measures

Name	Time	Method
vasoactive therapy	intraoperative period	hemodynamic fluctuations (hypotension, tachycardia, severe hypertensive crisis) which needed vasoactive therapy.